Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.
about
Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathwayCurrent phase II clinical data for ridaforolimus in cancer.Identification of phenotype-relevant differentially expressed genes in breast cancer demonstrates enhanced quantile discretization protocol's utility in multi-platform microarray data integration.Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling.Quantitative analysis of castration resistant prostate cancer progression through phosphoproteome signalingMouse models of prostate cancer: picking the best model for the question.Single luminal epithelial progenitors can generate prostate organoids in culture.AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axisTargeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia.B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancerAtg7 cooperates with Pten loss to drive prostate cancer tumor growth.Recent advances in prostate development and links to prostatic diseasesScreening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network.Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer.Mithramycin A induces apoptosis by regulating the mTOR/Mcl-1/tBid pathway in androgen-independent prostate cancer cells.Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivinHigh glucose-induced resistance to 5-fluorouracil in pancreatic cancer cells alleviated by 2-deoxy-D-glucose.Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1.Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic.High-throughput methods for combinatorial drug discovery.ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer.Correlating phosphoproteomic signaling with castration resistant prostate cancer survival through regression analysis.Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream mTOR, STAT3 and c-Myc.New insights into 4E-BP1-regulated translation in cancer progression and metastasis.Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer.The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer.Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer.Differential requirements of androgen receptor in luminal progenitors during prostate regeneration and tumor initiation.
P2860
Q28534009-4C4BB6A0-FB67-44BE-AC92-8F6FE20BBDFBQ30662689-B0151906-7096-43AA-9A0E-5E79879992C3Q31114458-1CB7D1CC-BBEC-453F-890A-E21346525E11Q33589156-7AF30B0A-47F7-4EDE-A0E6-A2A9FDAAE073Q33651942-74A04428-3588-4ABD-AF1B-65E80BA85508Q33940867-3528C4D8-E0AA-4F03-B95D-988E74ACF875Q34282951-7F033C43-0AD8-419B-9A56-A7036DD63DB7Q35987253-9815DD2B-6E28-4335-B3A0-19B0C7BD6703Q36214081-761CDDE2-8001-493C-87AF-C14CE60DF1EBQ36243554-0DE24093-B78C-4DFF-B5AF-1C87D267F6D2Q36603857-5B96F02B-60A3-45C8-881C-8A4EB79C32AEQ36642727-41770E80-298F-45EF-83F4-F5562D6159AEQ36685517-82670D77-EA41-4F2E-908A-487BC9897EBEQ36926098-8621140A-97D5-46D3-BF2F-6715CC9F47DBQ37093269-1FB90ADD-8A99-4D6F-BCE2-64DEF79AB332Q37139070-86771464-5D70-4769-A4CB-5D78AD6D891EQ37176520-7BE0B137-52D1-4D16-B14C-25694F3E4A6CQ37438760-D429EC14-B2F2-40EA-B071-B147269CC60AQ37567719-42291614-D047-4FB3-8413-FF9C6FF7BD46Q37628984-034F0F15-ACB7-4897-9052-CAA94052B23BQ37707078-A8099598-8181-4F99-9C78-85876A4BAD52Q38056848-30AF9770-B8EB-47FC-A5B0-2F6EC80FA9BBQ38148743-5A1055F7-F92E-46FC-9276-4B0FB4D10917Q38532510-022E9AC8-610A-4141-9823-2577BC9891BCQ38540474-42C1023A-5B8E-4FBA-8A06-A6E09C3F307FQ38836163-DEDADDD5-050A-44CC-9991-4A5CBE7747D0Q38895320-DA6AE603-82B7-43A0-850B-2B016F326707Q39119297-9ECE8C00-C329-4283-9D15-6A5C0EEAD8F2Q40555570-C3A76F91-2E13-4DB9-A21D-B80A4AE2BC25Q40948168-4E843CA4-44EF-45C8-9D62-5434198F4908Q41865902-FAD5595A-23E5-412D-89E5-F7A66957ADE8Q43127413-1C9503E6-9B73-491A-BFFD-24F0DFA2286DQ47094892-7D65FA59-C344-4CAA-A5BD-C846DE1848ABQ48243350-54B98C47-A03B-4FB9-952D-D946948C40B7
P2860
Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Dual targeting of the Akt/mTOR ...... ically engineered mouse model.
@ast
Dual targeting of the Akt/mTOR ...... ically engineered mouse model.
@en
type
label
Dual targeting of the Akt/mTOR ...... ically engineered mouse model.
@ast
Dual targeting of the Akt/mTOR ...... ically engineered mouse model.
@en
prefLabel
Dual targeting of the Akt/mTOR ...... ically engineered mouse model.
@ast
Dual targeting of the Akt/mTOR ...... ically engineered mouse model.
@en
P2093
P2860
P50
P1433
P1476
Dual targeting of the Akt/mTOR ...... tically engineered mouse model
@en
P2093
Antonina Mitrofanova
Carolyn Waugh Kinkade
Celine Lefebvre
Cory Abate-Shen
Nicolas Floc'h
Robert D Cardiff
Takashi Kobayashi
P2860
P304
P356
10.1158/0008-5472.CAN-12-0283
P407
P577
2012-07-19T00:00:00Z